Embecta

EMBC

Market cap $201M

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Embecta (EMBC) To Contact Him Directly To Discuss Their Options

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

New York, New York--(Newsfile Corp. - May 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Embecta Corp. ("Embecta Corp.") (NASDAQ: EMBC) concerning potential violations of the federal securities laws. On November 25, 2025, CFO Jacob P.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 5, 2026, the Company reported second quarter 2026 earnings, which announced results below analyst expec.

Embecta's Q2 FY2026 revenue and EPS fell short of both company guidance and Wall Street consensus -- shares dropped more than 25% in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Investors who held Embecta Corp. (NASDAQ: EMBC) shares lost more than 25% of their value when the stock collapsed after Q2 FY2026 earnings missed on both the top and bottom lines.

Embecta NASDAQ: EMBC President and CEO Devdatt Kurdikar said the company's recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification strategy intended to make the business less dependent on its core insulin injection franchise.

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced transaction to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug delivery technologies.

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (NASDAQ: EMBC) stock dropped more than 25% after the company reported Q2 FY2026 earnings release, which reported results below analyst expectations and included a reduction to full-year 2026 guidance. Shareholders who lost money on their Embecta investment are encouraged to submit their information here.

Embecta Corp. (EMBC) Presents at Bank of America Global Healthcare Conference 2026 Transcript